Genmab A/S (GMAB) - Total Assets
Based on the latest financial reports, Genmab A/S (GMAB) holds total assets worth Dkr7.02 Billion DKK (≈ $1.10 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Genmab A/S for net asset value and shareholders' equity analysis.
Genmab A/S - Total Assets Trend (2002–2024)
This chart illustrates how Genmab A/S's total assets have evolved over time, based on quarterly financial data.
Genmab A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
Genmab A/S's total assets of Dkr7.02 Billion consist of 60.8% current assets and 39.2% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 21.5% |
| Accounts Receivable | Dkr6.59 Billion | 14.4% |
| Inventory | Dkr62.00 Million | 0.1% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr12.34 Billion | 26.9% |
| Goodwill | Dkr2.54 Billion | 5.5% |
Asset Composition Trend (2002–2024)
This chart illustrates how Genmab A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Genmab A/S market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Genmab A/S's current assets represent 60.8% of total assets in 2024, a decrease from 89.6% in 2002.
- Cash Position: Cash and equivalents constituted 21.5% of total assets in 2024, up from 16.0% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 31.0% of total assets, an increase from 4.0% in 2002.
- Asset Diversification: The largest asset category is intangible assets at 26.9% of total assets.
Genmab A/S Competitors by Total Assets
Key competitors of Genmab A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Genmab A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.03 | 5.17 | 15.00 |
| Quick Ratio | 6.01 | 5.15 | 15.20 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr3.73 Billion | Dkr19.11 Billion | Dkr17.54 Billion |
Genmab A/S - Advanced Valuation Insights
This section examines the relationship between Genmab A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.24 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 29.8% |
| Total Assets | Dkr45.81 Billion |
| Market Capitalization | $16.33 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Genmab A/S's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Genmab A/S's assets grew by 29.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Genmab A/S (2002–2024)
The table below shows the annual total assets of Genmab A/S from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Dkr45.81 Billion ≈ $7.17 Billion |
+29.82% |
| 2023-12-31 | Dkr35.29 Billion ≈ $5.52 Billion |
+17.17% |
| 2022-12-31 | Dkr30.12 Billion ≈ $4.71 Billion |
+22.30% |
| 2021-12-31 | Dkr24.63 Billion ≈ $3.85 Billion |
+16.48% |
| 2020-12-31 | Dkr21.14 Billion ≈ $3.31 Billion |
+39.61% |
| 2019-12-31 | Dkr15.14 Billion ≈ $2.37 Billion |
+78.99% |
| 2018-12-31 | Dkr8.46 Billion ≈ $1.32 Billion |
+28.14% |
| 2017-12-31 | Dkr6.60 Billion ≈ $1.03 Billion |
+26.05% |
| 2016-12-31 | Dkr5.24 Billion ≈ $819.56 Million |
+34.23% |
| 2015-12-31 | Dkr3.90 Billion ≈ $610.58 Million |
+36.13% |
| 2014-12-31 | Dkr2.87 Billion ≈ $448.51 Million |
+65.56% |
| 2013-12-31 | Dkr1.73 Billion ≈ $270.91 Million |
+2.28% |
| 2012-12-31 | Dkr1.69 Billion ≈ $264.86 Million |
+8.21% |
| 2011-12-31 | Dkr1.56 Billion ≈ $244.77 Million |
-36.96% |
| 2010-12-31 | Dkr2.48 Billion ≈ $388.26 Million |
+11.71% |
| 2009-12-31 | Dkr2.22 Billion ≈ $347.58 Million |
-31.83% |
| 2008-12-31 | Dkr3.26 Billion ≈ $509.89 Million |
-17.68% |
| 2007-12-31 | Dkr3.96 Billion ≈ $619.38 Million |
+119.37% |
| 2006-12-31 | Dkr1.80 Billion ≈ $282.35 Million |
+31.68% |
| 2005-12-31 | Dkr1.37 Billion ≈ $214.41 Million |
+7.75% |
| 2004-12-31 | Dkr1.27 Billion ≈ $199.00 Million |
+7.78% |
| 2003-12-31 | Dkr1.18 Billion ≈ $184.64 Million |
-25.46% |
| 2002-12-31 | Dkr1.58 Billion ≈ $247.69 Million |
-- |
About Genmab A/S
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervic… Read more